Printer Friendly

Volcano Therapeutics, Inc. Announces Addition of Goodman Company, Ltd. as Japanese IVUS Distribution Partner.

RANCHO CORDOVA, Calif., Oct. 5 /PRNewswire/ -- Volcano Therapeutics, Inc., a leading developer and manufacturer of intravascular ultrasound ("IVUS") products, announced an agreement today to add Goodman Company, Ltd. to distribute IVUS products in Japan beginning February 1, 2005. Volcano's current distributors, Fukuda Denshi and Johnson & Johnson Cordis will continue to distribute Volcano's IVUS products to their existing customers while Goodman will distribute to all other hospitals in Japan.

Scott Huennekens, President & CEO of Volcano Therapeutics, noted, "Volcano is focused on providing interventional cardiologists and the medical community advanced technologies to better understand the development and progression of atherosclerosis and vulnerable plaques. Japan is the largest IVUS market in the world and it is critically important for us to partner with the best IVUS distributor in Japan. We believe Goodman provides Volcano the best opportunity to serve the Japanese interventional cardiology market, introduce our exciting array of new technologies, and move Volcano into a market leadership position in Japan. Goodman developed the IVUS market in Japan and has been the market leader in Japan for over ten years while distributing for another manufacturer. Through Goodman and our existing distributors we plan to introduce Virtual Histology(TM) IVUS tissue characterization technology* and an important new IVUS catheter platform in Japan in 2005."

Investigators participating in the initial Virtual Histology IVUS registry study in Japan include Takahiko Suzuki, M.D., and Osamu Katoh, M.D., from Toyohashi Heart Center, Toyohashi, Japan. Dr. Katoh commented, "Virtual Histology IVUS affords assessment of underlying plaque histopathology. We hope that this information will reveal important correlations between disease states and underlying arterial structure. The preliminary findings from our initial clinical trial are extremely encouraging."

Akira Yamamoto, President of Goodman, added, "We are very excited to expand our distribution agreement with Volcano beyond Functional Measurement products to include Volcano's IVUS products and exciting next generation IVUS technologies. Volcano is developing the most innovative new products that address critically important clinical needs. The products in Volcano's pipeline will enable Goodman to maintain and grow its IVUS market share leadership position in 2006 and beyond."

* Volcano's IVUS tissue characterization technology is Pending 510(K) Review -- not available for sale in the United States

About Volcano Therapeutics, Inc.

Volcano Therapeutics, Inc. is a privately held medical device company founded in 2001 and now has over 400 employees. The company is focused on the discovery, development and commercialization of products for the detection and treatment of atherosclerosis and vulnerable plaques in the coronary arteries and peripheral vascular system. Volcano products include IVUS and physiology guide wires. With global distribution, Volcano Therapeutics, Inc. is a leading provider of innovative diagnostic solutions to the interventional cardiology field. For more information, please visit

CONTACT: United States and Japan, Scott Huennekens, President & CEO, or Vince Burgess, Vice President of Marketing & Business Development, both of Volcano Therapeutics, Inc., +1-916-638-8008, or fax, +1-916-638-8112

Web site:
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Oct 5, 2004
Previous Article:Smarthome Announces Winners of 'Automate This!' Contest; Automated Bathtub Wins First Prize, Device to Restrict Children's Television Viewing and...
Next Article:Research and Markets: Intriguing Exploration of the 'Local Paid Search Advertising' Phenomenon.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters